These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 14623961)

  • 21. Point mutations in anthrax protective antigen that block translocation.
    Sellman BR; Nassi S; Collier RJ
    J Biol Chem; 2001 Mar; 276(11):8371-6. PubMed ID: 11113126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design.
    Karginov VA; Nestorovich EM; Moayeri M; Leppla SH; Bezrukov SM
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15075-80. PubMed ID: 16214885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An anthrax lethal factor mutant that is defective at causing pyroptosis retains proapoptotic activity.
    Ngai S; Batty S; Liao KC; Mogridge J
    FEBS J; 2010 Jan; 277(1):119-27. PubMed ID: 19922472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PA63 channel of anthrax toxin: an extended beta-barrel.
    Nassi S; Collier RJ; Finkelstein A
    Biochemistry; 2002 Feb; 41(5):1445-50. PubMed ID: 11814336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the Bacillus anthracis 20 kDa protective antigen component.
    Hammamieh R; Ribot WJ; Abshire TG; Jett M; Ezzell J
    BMC Infect Dis; 2008 Sep; 8():124. PubMed ID: 18808698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-association of the transmembrane domain of an anthrax toxin receptor.
    Go MY; Kim S; Partridge AW; Melnyk RA; Rath A; Deber CM; Mogridge J
    J Mol Biol; 2006 Jun; 360(1):145-56. PubMed ID: 16756998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure of the Anthrax Protective Antigen D425A Dominant Negative Mutant Reveals a Stalled Intermediate State of Pore Maturation.
    Scott H; Huang W; Andra K; Mamillapalli S; Gonti S; Day A; Zhang K; Mehzabeen N; Battaile KP; Raju A; Lovell S; Bann JG; Taylor DJ
    J Mol Biol; 2022 May; 434(9):167548. PubMed ID: 35304125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.
    Wu G; Feng C; Hong Y; Guo A; Cao S; Dong J; Lin L; Liu Z
    Appl Microbiol Biotechnol; 2010 Jun; 87(2):609-16. PubMed ID: 20213183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.
    Li ZN; Mueller SN; Ye L; Bu Z; Yang C; Ahmed R; Steinhauer DA
    J Virol; 2005 Aug; 79(15):10003-12. PubMed ID: 16014960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo.
    Little SF; Webster WM; Fisher DE
    FEMS Immunol Med Microbiol; 2011 Jun; 62(1):11-22. PubMed ID: 21231965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lethal factor of anthrax toxin binds monomeric form of protective antigen.
    Chvyrkova I; Zhang XC; Terzyan S
    Biochem Biophys Res Commun; 2007 Aug; 360(3):690-5. PubMed ID: 17617379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular model of anthrax toxin translocation into target-cells].
    Noskov AN
    Bioorg Khim; 2014; 40(4):399-404. PubMed ID: 25898749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.
    Mechaly A; Levy H; Epstein E; Rosenfeld R; Marcus H; Ben-Arie E; Shafferman A; Ordentlich A; Mazor O
    J Biol Chem; 2012 Sep; 287(39):32665-73. PubMed ID: 22869370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.
    Sellman BR; Mourez M; Collier RJ
    Science; 2001 Apr; 292(5517):695-7. PubMed ID: 11326092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of domain II in toxicity of anthrax lethal factor.
    Liang X; Young JJ; Boone SA; Waugh DS; Duesbery NS
    J Biol Chem; 2004 Dec; 279(50):52473-8. PubMed ID: 15465830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.
    Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB
    FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthrax-toxin-mediated delivery of a 19 kDa antigen of Mycobacterium tuberculosis into the cytosol of mammalian cells.
    Mehra V; Khanna H; Chandra R; Singh Y
    Biotechnol Appl Biochem; 2001 Apr; 33(2):71-4. PubMed ID: 11277858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constitutive expression of protective antigen gene of Bacillus anthracis in Escherichia coli.
    Chauhan V; Singh A; Waheed SM; Singh S; Bhatnagar R
    Biochem Biophys Res Commun; 2001 May; 283(2):308-15. PubMed ID: 11327699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin.
    Khanna H; Gupta PK; Singh A; Chandra R; Singh Y
    Biol Chem; 2001 Jun; 382(6):941-6. PubMed ID: 11501759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthrax protective antigen cleavage and clearance from the blood of mice and rats.
    Moayeri M; Wiggins JF; Leppla SH
    Infect Immun; 2007 Nov; 75(11):5175-84. PubMed ID: 17724066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.